These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34388457)

  • 1. OBHS impairs the viability of breast cancer via decreasing ERα and Atg13.
    Zhou J; Shen R; Zhou HB; Huang J
    Biochem Biophys Res Commun; 2021 Oct; 573():69-75. PubMed ID: 34388457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor α antagonism.
    Wu J; Yan J; Fang P; Zhou HB; Liang K; Huang J
    Cancer Lett; 2020 Jan; 469():78-88. PubMed ID: 31629931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
    Tang C; Li C; Zhang S; Hu Z; Wu J; Dong C; Huang J; Zhou HB
    J Med Chem; 2015 Jun; 58(11):4550-72. PubMed ID: 25993269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
    Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
    PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer.
    Ning W; Hu Z; Tang C; Yang L; Zhang S; Dong C; Huang J; Zhou HB
    J Med Chem; 2018 Sep; 61(18):8155-8173. PubMed ID: 30053783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
    Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
    He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.
    Bowers LW; Cavazos DA; Maximo IX; Brenner AJ; Hursting SD; deGraffenried LA
    Breast Cancer Res; 2013; 15(4):R59. PubMed ID: 23880059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
    Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
    Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
    Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
    Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
    Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
    Luo G; Tang Z; Lao K; Li X; You Q; Xiang H
    Eur J Med Chem; 2018 Apr; 150():783-795. PubMed ID: 29587221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
    Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
    Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells.
    Chen X; Ma N; Zhou Z; Wang Z; Hu Q; Luo J; Mei X; Yang Z; Zhang L; Wang X; Feng Y; Yu X; Ma J; Guo X
    Med Sci Monit; 2017 Jun; 23():2674-2683. PubMed ID: 28570501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ICI 182,780, an ERα and ERβ antagonist, and G-1, a GPER agonist, on autophagy in breast cancer cells.
    Muler ML; Antunes F; Guarache GC; Oliveira RB; Ureshino RP; Bincoletto C; Pereira GJDS; Smaili SS
    Einstein (Sao Paulo); 2020; 18():eAO4560. PubMed ID: 32321078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.